Financial Comparison
Cipla Limited vs Sun Pharmaceutical Industries Limited
Click a ticker to view the full analysis.
In short
Sun Pharmaceutical Industries Limited is the more profitable of the two, keeping 19.7% of revenue as net profit against 14.0% for Cipla Limited. Cipla Limited trades at the higher trailing P/E (39.0× vs 38.8× for Sun Pharmaceutical Industries Limited), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for Cipla Limited and 0 for Sun Pharmaceutical Industries Limited.
Based on filings for periods ending 31 Mar 2026 (CIPLA.NS) and 31 Mar 2026 (SUNPHARMA.NS) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. CIPLA.NS shown solid · SUNPHARMA.NS shown dashed. Not financial advice.
| Metric | CIPLA.NS | SUNPHARMA.NS |
|---|---|---|
| Price | ₹1,397.10 | ₹1,773.40 |
| Market Cap | ₹1.13T | ₹4.25T |
| P/E (TTM) | 39.0x | 38.8x |
| P/B | 3.2x | 4.8x |
| Beta | 0.10 | 0.13 |
| Div Yield | 0.93% | 0.90% |
| Revenue (TTM) | ₹277.1B | ₹582.2B |
| Net Income | ₹38.8B | ₹114.8B |
| Gross Margin | 62.3% | 77.4% |
| Risk Flags | — | — |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.